What is Cotellic used for?

Cotellic (cobimetinib) is an orally administered kinase inhibitor used to treat advanced melanoma (skin cancer) in patients with an abnormal genetic marker known as a BRAF V600E or V600K.

Cotellic is used in combination with vemurafenib (Zelboraf).

BRAF and MEK are proteins in a cell signaling pathway that help control cell growth and survival. Vemurafenib is designed to inhibit some mutated forms of BRAF, and Cotellic is designed to inhibit some forms of MEK. When used in combination, Cotellic and vemurafenib are thought to reduce cancer cell growth longer than with vemurafenib alone.

Cotellic is also used to treat histiocytic neoplasms, a group of rare diseases caused by overproduction of the white blood cells called histiocytes. The diseases include Erdheim-Chester disease, Rosai-Dorfman disease, and Langerhans cell histiocytosis.

See also:

Related medical questions

• How long does it take for Keytruda to work?
• Pembrolizumab vs. nivolumab: How do they compare?
• How effective Is Keytruda for metastatic melanoma?
• How effective are Opdivo and Yervoy when taken together?
• Opdivo vs Opdivo Qvantig: What is the Difference?
• What is Braftovi used to treat?
• What is Mektovi used to treat?

Drug information

• Cotellic Information for Consumers
• Cotellic prescribing info & package insert (for Health Professionals)
• Side Effects of Cotellic (detailed)

Related support groups

• Cotellic (1 questions, 3 members)
• Melanoma - Metastatic (8 questions, 30 members)

Medical Disclaimer